The Infectious Diseases Society of America (IDSA) applauds Senator Michael Bennet (D-CO) and Orrin Hatch (R-UT) for introducing the Promise for Antibiotics and Therapeutics for Health (PATH) Act, legislation to establish a new limited population antibacterial drug approval pathway for antibacterial drugs to treat serious or life-threatening infections where there exists an unmet medical need.
“Patients are dying from multi-drug resistant infections, and we desperately need new antibiotics to save their lives. The PATH Act will create a feasible approval pathway that will allow these drugs to be brought to market,” explains IDSA president Steve Calderwood, MD, FIDSA.
Under current law, many of the most urgently needed antibiotics to treat some of the most deadly and highly resistant infections are not being developed because companies cannot fill large, traditional clinical trials as these infections currently occur in a relatively small number of patients. But we need to start developing drugs to treat these infections before greater numbers of patients become ill. The PATH Act will allow these drugs to be studied in smaller clinical trials and approved for the limited population of patients who need them.
“Importantly, the PATH Act will not only help spur the development of urgently needed new antibiotics. The legislation will also help ensure these precious new drugs are used appropriately to limit the development of resistance,” says Calderwood. Specifically, the PATH Act requires clear labeling of drugs approved under this pathway (through a logo or other such means), pre-review of marketing materials, and monitoring the use of drugs approved under this pathway, as well as patterns of resistance.
In its September report, the President’s Council of Advisors on Science and Technology (PCAST) explicitly recommended the enactment of legislation to establish a new approval pathway for antibiotics to be used in limited populations of patients. “There is clear agreement among medical, scientific, and public health leaders that the federal government must act to stimulate development of urgently needed new antibiotics. There is broad support for the limited population antibacterial drug pathway which the PATH Act would establish. Congress must continue the momentum driving this issue on behalf of patients. IDSA looks forward to working with Senators Bennet and Hatch to enact the PATH Act,” Calderwood adds.
Source: IDSA
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.